BrightGene Bio Medical Technology C
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also pr… Read more
BrightGene Bio Medical Technology C (688166) - Net Assets
Latest net assets as of June 2025: CN¥2.59 Billion CNY
Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has net assets worth CN¥2.59 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.38 Billion) and total liabilities (CN¥2.80 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.59 Billion |
| % of Total Assets | 48.04% |
| Annual Growth Rate | 35.06% |
| 5-Year Change | 70.14% |
| 10-Year Change | N/A |
| Growth Volatility | 35.19 |
BrightGene Bio Medical Technology C - Net Assets Trend (2016–2024)
This chart illustrates how BrightGene Bio Medical Technology C's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BrightGene Bio Medical Technology C (2016–2024)
The table below shows the annual net assets of BrightGene Bio Medical Technology C from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.44 Billion | +0.82% |
| 2023-12-31 | CN¥2.42 Billion | +7.85% |
| 2022-12-31 | CN¥2.24 Billion | +28.71% |
| 2021-12-31 | CN¥1.74 Billion | +21.58% |
| 2020-12-31 | CN¥1.43 Billion | +9.10% |
| 2019-12-31 | CN¥1.31 Billion | +69.90% |
| 2018-12-31 | CN¥772.85 Million | +73.27% |
| 2017-12-31 | CN¥446.02 Million | +102.60% |
| 2016-12-31 | CN¥220.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BrightGene Bio Medical Technology C's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 98172002964.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥960.84 Million | 40.12% |
| Other Components | CN¥1.43 Billion | 59.88% |
| Total Equity | CN¥2.39 Billion | 100.00% |
BrightGene Bio Medical Technology C Competitors by Market Cap
The table below lists competitors of BrightGene Bio Medical Technology C ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tongyu Heavy Industry
SHE:300185
|
$1.46 Billion |
|
EUROCOMM.PR. CERT.10EO 10
F:N4SA
|
$1.46 Billion |
|
APERAM S.A. NY SHS/1 O.N.
F:7AAN
|
$1.46 Billion |
|
ELVALHALCOR NA EO 039
F:HC6A
|
$1.46 Billion |
|
Gentera S.A.B. de C.V
OTCGREY:CMPRF
|
$1.46 Billion |
|
Upwork Inc
NASDAQ:UPWK
|
$1.46 Billion |
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
$1.46 Billion |
|
Griffin-American Healthcare REIT III Inc
PINK:GRAH
|
$1.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BrightGene Bio Medical Technology C's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,368,615,404 to 2,394,647,561, a change of 26,032,157 (1.1%).
- Net income of 189,166,937 contributed positively to equity growth.
- Dividend payments of 135,734,274 reduced retained earnings.
- Other factors decreased equity by 27,400,506.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥189.17 Million | +7.9% |
| Dividends Paid | CN¥135.73 Million | -5.67% |
| Other Changes | CN¥-27.40 Million | -1.14% |
| Total Change | CN¥- | 1.10% |
Book Value vs Market Value Analysis
This analysis compares BrightGene Bio Medical Technology C's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.48x to 7.89x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥9.99 | CN¥44.72 | x |
| 2018-12-31 | CN¥15.98 | CN¥44.72 | x |
| 2019-12-31 | CN¥3.20 | CN¥44.72 | x |
| 2020-12-31 | CN¥3.49 | CN¥44.72 | x |
| 2021-12-31 | CN¥4.09 | CN¥44.72 | x |
| 2022-12-31 | CN¥5.19 | CN¥44.72 | x |
| 2023-12-31 | CN¥5.61 | CN¥44.72 | x |
| 2024-12-31 | CN¥5.67 | CN¥44.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BrightGene Bio Medical Technology C utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.90%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.75%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 2.16x
- Recent ROE (7.90%) is below the historical average (9.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 7.75% | 8.49% | 0.52x | 1.75x | CN¥-4.95 Million |
| 2017 | 10.29% | 14.48% | 0.60x | 1.18x | CN¥1.27 Million |
| 2018 | 9.47% | 17.96% | 0.46x | 1.14x | CN¥-4.08 Million |
| 2019 | 8.46% | 22.08% | 0.35x | 1.08x | CN¥-20.23 Million |
| 2020 | 11.87% | 21.63% | 0.43x | 1.28x | CN¥26.70 Million |
| 2021 | 14.54% | 23.18% | 0.35x | 1.77x | CN¥76.13 Million |
| 2022 | 10.93% | 23.55% | 0.22x | 2.13x | CN¥20.46 Million |
| 2023 | 8.55% | 17.17% | 0.23x | 2.12x | CN¥-34.40 Million |
| 2024 | 7.90% | 14.75% | 0.25x | 2.16x | CN¥-50.30 Million |
Industry Comparison
This section compares BrightGene Bio Medical Technology C's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BrightGene Bio Medical Technology C (688166) | CN¥2.59 Billion | 7.75% | 1.08x | $1.46 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |